Boehringer Ingelheim set to receive EUR 90 million as upfront payment, along with milestone payments and tiered royalties.

Boehringer Ingelheim & LEO Pharma partner to commercialize and further develop Spevigo: Ingelheim, Germany Wednesday, July 16, 2025, 15:00 Hrs [IST] Boehringer Ingelheim, a biopha ...

New research identifies diabetes as an independent predictor of major adverse cardiovascular events in patients with both ...

From polyaphron technology to fixed combinations, new formulations improve tolerability, adherence, and patient satisfaction. Join Drs Feldman and Armstrong as they discuss.